Laparoscopic ovariectomy represents a paradigm shift in veterinary sterilization, offering reduced pain scores and faster ...
A total of 599 patient data entry forms out of 600 with an equal distribution of genders (49% men, 51% women) and a mean age of 57 years (SD 19 years) were available for analysis. An open approach was ...
The approval of subcutaneous amivantamab allows physicians flexibility in offering treatment for non–small cell lung cancer. Martin Dietrich, MD, PhD, a medical oncologist at the Cancer Care Centers ...
1 Ningde Clinical Medical College of Fujian Medical University, Ningde, Fujian, China 2 Department of Joint Surgery and Sports Medicine, Ningde Municipal Hospital of Ningde Normal University, Ningde, ...
Surgical wound tension, a core biomechanical factor in tissue repair, is clinically important because high tension can cause microcirculatory disturbances, leading to inhibition of cell migration and ...
Subcutaneous pembrolizumab with berahyaluronidase alfa is FDA-approved for all solid tumor indications, including metastatic nonsquamous NSCLC. The phase 3 3475A-D77 trial confirmed noninferior ...
Please provide your email address to receive an email when new articles are posted on . Patients who received subcutaneous amivantamab-vmjw every 4 weeks plus lazertinib had similar outcomes as those ...
A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective ...
The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase. Leqembi Iqlik is a subcutaneous ...
TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...
Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results